Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis.

Jafari, Morteza; Jabbary Lak, Fatemeh; Gazdhar, Amiq; Shafighi, Maziar; Borradori, Luca; Hunger, Robert (2018). Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis. European journal of dermatology EJD, 28(3), pp. 287-313. John Libbey Eurotext 10.1684/ejd.2018.3291

[img] Text
Application.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (439kB) | Request a copy

Electrochemotherapy is becoming a promising technique for the management of malignancies of skin and non-skin origin. The current review aims to clarify current knowledge on administration of electrochemotherapy for the treatment of various skin tumours. A systematic literature search was performed, up to the end of 2016, on studies in which the application of electrochemotherapy for management of primary and metastatic cutaneous malignant tumours was assessed. Having selected appropriate studies, pooled estimates of mean objective (complete) responses, with 95% confidence intervals (CIs), were calculated to assess treatment efficacy. Finally, the main emerging themes from the papers were discussed in more detail. From 465 records identified through database searching, a total of 128 studies were screened, of which 70 were included for review. After a pooled analysis, the estimate for mean objective response following electrochemotherapy was 84.02% (95% CI: 80.08-87.61). Furthermore, the pooled estimate of objective treatment response of evaluated studies was 83.91% (95% CI: 79.15-88.17%) for bleomycin and 80.82% (95% CI: 66.00-92.36%) for cisplatin. Electrochemotherapy is a feasible, inexpensive, fast and easy technique to perform local treatment, regardless of tumour type, with a low level of adverse effects and patient discomfort. This method can be applied alone for patients with primary cutaneous lesions, or local or locoregional metastases, or as an additional treatment modality in patients with distant metastases.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Pneumologie (Erwachsene)
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Jafari, Morteza; Gazdhar, Amiq; Borradori, Luca and Hunger, Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1167-1122

Publisher:

John Libbey Eurotext

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

30 Nov 2018 09:11

Last Modified:

03 Jan 2019 17:29

Publisher DOI:

10.1684/ejd.2018.3291

PubMed ID:

30105989

Uncontrolled Keywords:

clinical trials cutaneous malignant tumour electrochemotherapy metastasis

BORIS DOI:

10.7892/boris.121868

URI:

https://boris.unibe.ch/id/eprint/121868

Actions (login required)

Edit item Edit item
Provide Feedback